TANGO: Switch to DTG/3TC Maintains Virologic Suppression at Wk 48 Across Patient Demographics and Baseline Third Agent Classes

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
Switching from a TAF-based regimen to DTG/3TC maintains virologic suppression across patient subgroups regardless of patient demographics, disease characteristics, or baseline third agent.
Format: Microsoft PowerPoint (.ppt)
File Size: 191 KB
Released: November 8, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Slides from Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in experienced patients who are suppressed

John D. Baxter, MD Released: January 24, 2022

From Dr. Fidelia Bernice and Clinical Care Options (CCO), expert commentary on managing polypharmacy in people with HIV

Fidelia Bernice, PharmD Released: January 6, 2022

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Jean-Michel Molina, MD, PhD Cristina Mussini, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in patients with suppressed HIV-1 RNA, particularly if preexisting resistance is suspected

John D. Baxter, MD Released: December 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings